Patients (n) | 70 |
Clinical characteristics | |
Age (years) | 64.3 (61.9–66.6) |
Male (%) | 55.7 |
BMI (kg·m−2) | 27.96 (26.54–29.38) |
FFMI | 17.99 (16.95–19.04) |
Current smoking (%) | 42.9 |
Smoking (pack-years) | 43.9 (39.3–48.6) |
Exacerbations (previous 12 months) | 1.1 (0.8–1.4) |
0 (%) | 38.6 |
1 (%) | 35.7 |
≥2 (%) | 25.7 |
ICS use (%) | 74.3 |
LABA + LAMA + ICS (%) | 60.0 |
LABA + LAMA (%) | 8.6 |
ICS + LABA (%) | 11.4 |
ICS + LAMA (%) | 1.4 |
ICS only (%) | 1.4 |
LABA only (%) | 0.0 |
LAMA only (%) | 12.9 |
No inhaled medication (%) | 4.3 |
mMRC¶ | 4.0 (2.0–4.0) |
CAT¶ | 21.0 (15.0–39.0) |
SGRQ total | 53.86 (50.15–57.57) |
SGRQ symptoms | 67.31 (63.46–71.16) |
SGRQ activity | 72.00 (67.71–76.29) |
SGRQ impact | 39.60 (35.23–43.97) |
Chronic bronchitis (%) | 77.1 |
6-min walk distance (m)¶ | 343.5 (122.0–534.0) |
Fibrinogen (g·L−1)¶ | 3.30 (0.00–6.55) |
IgE (kIU·L−1)¶ | 60.00 (0.00–1297.00) |
Neutrophil–lymphocyte ratio¶ | 2.02 (0.92–6.79) |
Lung function parameters | |
Post-BD FEV1 (% pred) | 65.6 (61.5–69.6) |
Post-BD FEV1 (L) | 1.7 (1.6–1.9) |
Post-BD FVC (% pred) | 100.2 (96.3–104.0) |
Post-BD FVC (L) | 3.3 (3.1–3.5) |
FEV1 reversibility (%) | 10.9 (8.2–13.6) |
FEV1 reversibility (mL) | 143.3 (109.7–176.9) |
Post-BD FEV1/FVC ratio (%) | 52.6 (49.9–55.3) |
R5 (kPa·L−1·s−1) | 0.60 (0.56–0.65) |
R20 (kPa·L−1·s−1)¶ | 0.37 (0.23–0.66) |
R5–R20 (kPa·L−1·s−1) | 0.22 (0.19–0.25) |
AX | 2.96 (2.50–3.42) |
X5 (kPa·L−1·s−1)¶ | −0.30 (−0.92–0.07) |
ΔX5 (kPa·L−1·s−1)¶ | 0.25 (−0.05–1.48) |
TLC (L)¶ | 6.04 (3.75–9.47) |
TLC (% pred)¶ | 101.80 (73.89–144.50) |
FRC (L)¶ | 3.59 (1.69–6.79) |
FRC (% pred) | 117.10 (109.70–124.60) |
RV (L)¶ | 2.72 (1.48–5.58) |
RV (% pred)¶ | 122.80 (74.00–234.60) |
RV:TLC | 48.61 (46.37–50.86) |
DLCO (mmol·min-1·kPa-1)¶ | 4.25 (1.60–13.10) |
DLCO (% pred)¶ | 49.00 (21.00–108.00) |
KCO (mmol·min-1·kPa-1·L-1)¶ | 0.96 (0.33–4.26) |
KCO (% pred)¶ | 64.69 (26.00–148.00) |
VA (L) | 4.55 (4.29–4.80) |
VA (%) | 76.77 (73.92–79.63) |